Nanoconjugated Vancomycin Helps Spleen During VRSA Infection
Author Information
Author(s): Subhankari Prasad Chakraborty, Santanu KarMahapatra, Sumanta Kumar Sahu, Panchanan Pramanik, Somenath Roy
Primary Institution: Vidyasagar University
Hypothesis
The study aims to evaluate the antioxidant effects of nanoconjugated vancomycin against VRSA infection in the spleen.
Conclusion
Nanoconjugated vancomycin shows potential in protecting the spleen from oxidative stress and DNA damage caused by VRSA infection.
Supporting Evidence
- VRSA infection increased oxidative stress markers in the spleen.
- Nanoconjugated vancomycin treatment reduced oxidative damage and improved antioxidant status.
- Histopathological analysis showed recovery of spleen tissue after treatment.
Takeaway
This study found that a special form of vancomycin can help protect the spleen from damage caused by a tough bacteria called VRSA.
Methodology
Swiss mice were infected with VRSA and treated with nanoconjugated vancomycin for 10 days, followed by biochemical estimations of oxidative stress markers.
Potential Biases
Potential bias in the selection of animal models and the specific strain of VRSA used.
Limitations
The study was conducted on a small sample size of mice, which may limit the generalizability of the findings.
Participant Demographics
Twenty-four Swiss male mice, aged 6–8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website